Studies acoramidis tablets in adults with transthyretin amyloid heart disease
Tests acoramidis tablets in adults with heart disease caused by transthyretin amyloidosis.
Plain-language title generated from the registry record
Registry title: Cardiac Magnetic Resonance and Echocardiography Study With Acoramidis
Key facts
- Where
- Aarhus N, DenmarkSee the site
- Phase
- Phase 4
AI summary: who the study is looking for
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for adults aged 18 to 80 with a confirmed diagnosis of transthyretin amyloid cardiomyopathy (ATTR-CM) who need targeted therapy, to study the effect of acoramidis on the heart.
- Age
- 18 to 80 years
- Sex
- All sexes can join.
- Disease stage
- Confirmed ATTR-CM that needs targeted therapy. At screening: NYHA Class I/II, eGFR ≥40 mL/min/1.73m2, LVEF >35%, LV wall thickness ≥12 mm. Heart failure stable for at least 6 weeks before screening.
- Earlier treatment
- People cannot have had or be having treatment with acoramidis.
Main reasons for not taking part
- Current or planned cardiac implantable electronic device (eg, pacemaker, implantable cardiac defibrillator)
- Heart attack, acute coronary syndrome, coronary revascularization, stroke or transient ischemic attack within 90 days before screening
- Hemodynamic instability
- Likely to have a heart transplant within 12 months from screening
- AL amyloidosis, NYHA Class III/IV or National Amyloidosis Center (NAC) Stage 3 at screening
Read by machine on 12 November 2026.
Could this be for you?
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 18 and 80 years old?
Source: NCT07695701, who can take part
Where in Denmark
- Region MidtjyllandAarhus N, DenmarkNot yet recruiting
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorTrial details
- Who runs it
- Eidos Therapeutics, a BridgeBio company
- Trial code
- NCT07695701EU 2026-526068-19-00
- Record updated
- 29 July 2026
- Original description
The study aims to evaluate the effect of acoramidis on cardiac functional and structural improvement in participants with ATTR-CM.Read full original descriptionShow less
An Open-Label Study to Investigate the Long-Term Effects of Acoramidis on Cardiac Function, Structure and Cardiac Amyloid Burden in Participants With Transthyretin Amyloid Cardiomyopathy (ATTR-CM)
The study aims to evaluate the effect of acoramidis on cardiac functional and structural improvement in participants with ATTR-CM.
Inclusion: Participants aged 18 to 80; Confirmed diagnosis of ATTR-CM requiring targeted therapy; At screening: New York Heart Association (NYHA) Class I/II; estimated glomerular filtration rate (eGFR) ≥40 mL/min/1.73m2; left ventricular ejection fraction (LVEF) >35%; left ventricular (LV) wall thickness ≥12 mm; Heart failure condition has been clinically stable for at least 6 weeks prior to screening.
Exclusion: Acute myocardial infarction, acute coronary syndrome or coronary revascularization, or experienced stroke or transient ischemic attack within 90 days prior to screening; Prior or current treatment with acoramidis; Current or planned implantation of a cardiac implantable electronic device (eg, pacemaker, implantable cardiac defibrillator); Likely to undergo heart transplantation within 12 months from screening; Hemodynamic instability; Confirmed diagnosis of AL amyloidosis at screening; At screening: NYHA Class III/IV; National Amyloidosis Center (NAC) Stage 3.